Author

E. Davicioni

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. Sboner· 2 shared B. D. Robinson· 2 shared D. Liu· 2 shared F. Khani· 2 shared K. Lin· 2 shared L. D. Deonarine· 2 shared M. A. Augello· 2 shared O. Elemento· 2 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Sboner

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Canonical AREs are tumor suppressive regulatory elements in the prostate

M. A. Augello, X. Chen, D. Liu, K. Lin, A. Hakansson, M. Sjostrom, F. Khani, L. D. Deonarine, Y. Liu, J. Travascio-Green, J. Wu, M. Loda, F. Y. Feng, B. D. Robinson, E. Davicioni, , C. Barbieri

This study identifies canonical AREs as tumor suppressive regulatory elements in prostate cancer, showing their reactivation can induce death in AR+ cancer cells and is linked to better prognosis.

bioRxiv · Feb 23, 2024 · PreprintCancer Biology

SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape

I. Grbesa, M. A. Augello, D. Liu, D. R. McNally, C. D. Gaffney, D. Huang, K. Lin, R. Goueli, B. D. Robinson, F. Khani, L. D. Deonarine, M. Blattner, O. Elemento, E. Davicioni, A. Sboner, C. E. Barbieri

This study shows that SPOP mutations in prostate cancer alter the chromatin landscape and AR-driven transcription, making tumors more responsive to AR-targeted therapies.

bioRxiv · Apr 20, 2021 · PreprintCancer Biology

Epigenetic analysis identifies factors driving racial disparity in prostate cancer

R. Rai, S. S. Yadav, H. Pan, J. O'Connor, M. Alshalalfa, E. Davicioni, E. Taioli, O. Elemento, A. K. Tewari, K. K. Yadav

The paper analyzes epigenetic differences between African American and Caucasian prostate cancer patients to identify factors contributing to racial disparities in disease aggressiveness and outcomes.

bioRxiv · Jun 20, 2018Cancer Biology